Jessica Robinson-Papp, MD, MS
- ASSOCIATE PROFESSOR | Neurology
- Hospital Affiliation
- The Mount Sinai Hospital
Dr. Robinson-Papp’s clinical and research interests include neuropathy, and the neurologic complications of HIV/AIDS including chronic pain. She is the Director of the NeuroAIDS Program. https://icahn.mssm.edu/research/neuroaids
She is the recipient of grants from the National Institutes of Health (NIH) to study HIV-associated neuropathy, and from the Agency for Healthcare Research and Quality (AHRQ) to study methods of improving opioid prescribing safety, and is the Medical Director of the Manhattan HIV Brain Bank. https://icahn.mssm.edu/research/manhattan-hiv
In addition to her research, Dr. Robinson-Papp performs electromyography (EMG), autonomic testing, and intraoperative neurologic monitoring, to aid in the diagnosis of neurologic disorders. She is the senior attending neurologist for the Institute for Advanced Medicine, where she provides neurologic care to people living with HIV/AIDS.
- Autonomic Disorder
- Carpal Tunnel Syndrome
- Chronic Inflammatory Demyelinating Neuropathy
- Diabetic Neuropathy
- Electrodiagnostic Testing (EMG/NCS)
- Low Back Pain
- Lumbar Radiculopathy
- Mononeuropathy Multiplex
- Peripheral Neuropathy
- Post-Herpetic Neuralgia (PHN)
- Progressive Multifocal Leukoencephalopathy
- Small Fiber Neuropathy
MD, Icahn Medical School at Mount Sinai
MS, Mount Sinai Graduate School of Biological Sciences
Internship, Internal Medicine
St. Vincent's Hospital [CLOSED]
Mount Sinai Hospital
Mount Sinai Hospital
Toward safer opioid prescribing for chronic pain in high risk populations: implementing the Centers for Disease Control (CDC) guideline in the primary care HIV clinic (TOWER; AHRQ R18 HS025641)This project engages patients and their helathcare providers in a collaborative process to develop and test a method of prescribing opioids more safely.Role: Principal Investigator
Manhattan HIV Brain Bank (NIH U24 MH100931)
This is a longitudinal organ donation study examining the neurologic, neuropsychological, psychiatric, and pathological effects of HIV.
Role: Co-investigator and Medical Director
Hippocampal Inflammation as a Pathophysiology for Psychosis (NIH R01 MH110418)This grant explores the gut-brain axis in psychosis with a focus on vagal dysfunction.Role: Co-investigator
Motor Dysfunction in cART-era HIV: Neural Circuitry and Pathogenesis (NIH R01 MH100931)
This study will use neurogenomics to identify molecular changes in brain regions associated with motor dysfunction in HIV on neuroimaging studies.
Mount Sinai Network of Excellence in Neuroscience Clinical Trials (NIH U24 NS107201)Mount Sinai is a participating site in NeuroNEXT, a consortium of sites committed to participating in clinical trials of therapeutics for a variety of neurologic conditions.Role: Co-investigator
Alzheimer's, Cerebrovascular, & Sociocultural Risk Factors for Dementia in HIVThe purpose of this study is to improve the knowledge and understanding of the effects of social, cultural and genetic factors associated with aging and cognition in HIV.Role: Site Principal Investigator
Peripheral Neuropathy Registry Research Protocol
The purpose of the study is to develop a multi-center cohort of well-characterized peripheral neuropathy patients with and without neuropathic pain in a natural history study.
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy
A phase 2, Randomized, Double-blind, Placebo-controlled, 6-week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects with Pain Caused by Small Fiber Neuropathy
Meet Our Team
• Mary Catherine George, Senior Research Program Manager • Gabriella Cedillo, Coordinator • Alexandra Nmashie, MD WEBSITE LINKS https://icahn.mssm.edu/research/neuroaids https://icahn.mssm.edu/research/manhattan-hiv
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Robinson-Papp did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.